A Whole-genome Sequencing Base Study on Genetic Pathogenesis of Diminished Ovarian Reserve
试验速览
- 阶段
- 不适用
- 入组人数
- 140
- 试验地点
- 1
- 主要终点
- Genotype
研究概览
简要总结
The study aims to explore the genetic pathogenesis of diminished ovarian reserve via whole-genome sequencing technology in Chinese women.
详细描述
Diminished ovarian reserve (DOR), a pathological condition of reduced quantity and quality of oocytes, has severe impairment on women fertility. Some women experience DOR may develop into premature ovarian insufficiency (POI), which defined as a cessation of function of ovaries in women younger than 40 years old. The pathogenesis of DOR is multiple and the etiology of most DOR remains obscure. Genetic factors, including chromosome abnormality, genetic variation, and non-coding RNA abnormal regulation are considered the major mechanisms of DOR. More than 12 gene mutations, detected by whole-exome sequencing (WES), have been implicated as potential causes of DOR. However, we have found that coding gene mutation detected by WES may only account for a small part of DOR. Whole-genome sequencing (WGS) has been developing into an important strategy for identifying exons, introns and mitochondrial DNA mutation. However, the application of WGS is still lacking in detecting pathogenic genes of DOR. Therefore, this study intends to explore the possible pathogenic genes by WGS in order to deeply and comprehensively understand the pathogenic mechanism of DOR.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 40 Years(Adult)
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •age between 18 and 40 years;
- •number of oocytes obtained in previous ovarian stimulation cycles ≤3;
- •bilateral ovarian antral follicle count (AFC) < 5-7;
- •serum anti-Mullerian hormone (AMH) <0.5-1.1ng/ml.
- •Control group:
- •age between 18 and 40 years;
- •bilateral AFC ≥8;
- •serum AMH ≥1.2ng/ml;
- •regular menstrual cycles occurring every 25-35 days.
排除标准
- •The exclusion criteria of the two groups were:
- •an abnormal karyotype;
- •a history of other endocrine diseases such as polycystic ovary syndrome, hyperprolactinemia and hyperthyroidism;
- •a history of radiotherapy, chemotherapy and ovarian surgery.
结局指标
主要结局
Genotype
时间窗: 1/9/2020-31/12/2022
Measure the genotype by whole-genome sequencing in all participates.
次要结局
未报告次要终点
